Table 3 Emerging targets with clinical significance in PC
Molecular target | Class | Trial | Disease setting | Agent | Experimental treatment | Study phase | Estimated completion |
|---|---|---|---|---|---|---|---|
Hormonal Therapy | Second-generation ADT | NCT03098836 | mCRPC | Apalutamide | Apalutamide + abiraterone | Phase II | June 2021 |
NCT02106507 | mCRPC | Apalutamide | Apalutamide +everolimus | Phase I | April 2020 | ||
NCT02489318 (TITAN) | mCSPC | Apalutamide | Apalutamide + ADT | Phase III | July 2022 | ||
New-generation ADT | NCT02200614 (ARAMIS) | nmCRPC | Darolutamide | Darolutamide | Phase III | June 2020 | |
AR inhibitor | NCT02445976 | CRPC Progressing on Enzalutamide or Abiraterone | Seviteronel | Seviteronel | Phase II | January 2019* | |
NCT02012920 | CRPC | Seviteronel | Seviteronel | Phase II | January 2019* | ||
Tumor Vaccine | Dendritic Cells | NCT02111577 (VIABLE) | mCRPC | DCVAC | DCVAC | Phase III | June 2020 |
PD-L1 and CTLA-4 | CPI | NCT02861573 (KEYNOTE-365) | mCRPC | Pembrolizumab + olaparib or Pembrolizumab + docetaxel + prednisone or Pembrolizumab + enzalutamide | Phase I | May 2022 | |
NCT02985957 (CheckMate-650) | mCRPC | Nivolumab + Ipilimumab | Phase II | March 2022 | |||
PD-L1 | NCT02787005 (KEYNOTE-199) | mCRPC | Pembrolizumab | Pembrolizumab monotherapy or Pembrolizumab + enzalutamide | Phase II | December 2020 | |
PARP Inhibitor | DNA Repair Inhibition | NCT03834519 (KEYLYNK-010) | mCRPC | Pembrolizumab + olaparib | Pembrolizumab + olaparib | Phase III | September 2022 |
NCT03732820 | Previously-untreated mCRPC | Abiraterone + olaparib | Abiraterone | Phase III | August 2022 | ||
Radioisotope | NCT03737370 | mCRPC | Radium-223 | Radium-223 + docetaxel | Phase I | October 2021 | |
ACTRN12615000912583** (LuPSMA Trial) | mCRPC | 177Lutetium | Phase I/II | N/A | |||